Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma (NCT04234048)
A Phase 1a/1b Trial in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma to Determine the Safety Profile, Pharmacology, and Maximum Tolerated Dose of ST-001, a Fenretinide Phospholipid Suspension (12.5 mg/mL) for Intravenous Infusion
🩺 Plain-English Summary (8th-Grade Level)
This study evaluates a fenretinide phospholipid suspension for the treatment of T-cell non-Hodgkin's lymphoma (NHL).
Who can join: Review the eligibility criteria below.
Location: Mayo Clinic Arizona — Scottsdale, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (10 Sites)
- Mayo Clinic Arizona — Scottsdale, Arizona
- City of Hope Medical Foundation — Duarte, California
- University of Southern California — Los Angeles, California
- University of Colorado Anschutz Medical Campus — Aurora, Colorado
- Northwestern University, Robert H. Lurie Comprehensive Cancer Center — Chicago, Illinois
- University of Michigan — Ann Arbor, Michigan
- Barbara Ann Karmanos Cancer Institute Wayne State University — Detroit, Michigan
- Columbia University — New York, New York
- University of Pittsburgh Medical Center (UPMC) — Pittsburgh, Pennsylvania
- The University of Texas MD Anderson Cancer Center — Houston, Texas
📞 Contact the Study Coordinator
Phone: (617) 283-2182
Email: lou@scitechdevelopment.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in T-cell Lymphoma
- A Study of Enasidenib in People With T-Cell Lymphoma — Basking Ridge, New Jersey
- A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma — Palo Alto, California
- CD4CAR for CD4+ Leukemia and Lymphoma — Miami, Florida
- Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma — New Haven, Connecticut
- A Registry for People With T-cell Lymphoma — Duarte, California
- Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma — Columbus, Ohio
Explore by condition: All T-cell Lymphoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.